The Quality Overall Summary (QOS) is an element of a drug marketing application that provides a substantially condensed summary of the quality-related data provided in the submission. Regulators can use the QOS to more effectively assess applications and more rapidly comprehend the quality information in the context of patient risk, including the proposed control strategy and any other planned steps to mitigate that risk. Patients benefit from the greater assessment efficiency by having improved access to drugs that are designed and manufactured to consistently and safely fulfill claims in the label.
News & Trends
Procurar
Recentes
- EMVO Systems Updates | May 2026
- EU agrees to simplify AI rules to boost innovation and ban ‘nudification’ apps to protect citizens
- Formação DIGITAL PROMO REVIEW : ” Formação muito interativa , bem estruturada e com elevada partilha de casos práticos “
- Best Practice Guidance for the Submission of Technical Documentation under Annex II and III of Medical Device Regulation
- COMMISSION IMPLEMENTING REGULATION laying down certain uniform quality management and procedural requirements for the conformity assessment activities carried out by a notified body designated
- MASTER COURSE SUPLEMENTOS ALIMENTARES : “Evento muito bem organizado, conduzido e menistrado “
- Guidelines on the best practices for the traceability of medicines in hospital settings
- MDCG 2021-12 Rev.2 FAQ on the European Medical Device Nomenclature (EMDN) Revision 2 – April 2026